关注
Jonas Cicenas
Jonas Cicenas
Data scientist, Max F. Perutz Laboratories, University of Vienna
在 mapkinases.eu 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 mutations in pancreatic cancer
J Cicenas, K Kvederaviciute, I Meskinyte, E Meskinyte-Kausiliene, ...
Cancers 9 (5), 42, 2017
2782017
The CDK inhibitors in cancer research and therapy
J Cicenas, M Valius
Journal of cancer research and clinical oncology 137, 1409-1418, 2011
2752011
Roscovitine in cancer and other diseases
J Cicenas, K Kalyan, A Sorokinas, E Stankunas, J Levy, I Meskinyte, ...
Annals of translational medicine 3 (10), 2015
2682015
The potential role of Akt phosphorylation in human cancers
J Cicenas
The International journal of biological markers 23 (1), 1-9, 2008
2062008
Highlights of the latest advances in research on CDK inhibitors
J Cicenas, K Kalyan, A Sorokinas, A Jatulyte, D Valiunas, A Kaupinis, ...
Cancers 6 (4), 2224-2242, 2014
1512014
KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma
J Cicenas, L Tamosaitis, K Kvederaviciute, R Tarvydas, G Staniute, ...
Medical oncology 34, 1-11, 2017
1502017
Kinases and cancer
J Cicenas, E Zalyte, A Bairoch, P Gaudet
Cancers 10 (3), 63, 2018
1352018
Non-coding RNAs in glioma
R Rynkeviciene, J Simiene, E Strainiene, V Stankevicius, J Usinskiene, ...
Cancers 11 (1), 17, 2018
1222018
JNK, p38, ERK, and SGK1 inhibitors in cancer
J Cicenas, E Zalyte, A Rimkus, D Dapkus, R Noreika, S Urbonavicius
Cancers 10 (1), 1, 2018
1022018
Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2
J Cicenas, P Urban, V Vuaroqueaux, M Labuhn, W Küng, E Wight, ...
Breast Cancer Research 7, 1-8, 2005
782005
Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients
J Cicenas, P Urban, W Küng, V Vuaroqueaux, M Labuhn, E Wight, ...
European Journal of Cancer 42 (5), 636-645, 2006
752006
The Aurora kinase inhibitors in cancer research and therapy
J Cicenas
Journal of cancer research and clinical oncology 142, 1995-2012, 2016
572016
Metabolomics in pancreatic cancer biomarkers research
J Tumas, K Kvederaviciute, M Petrulionis, B Kurlinkus, A Rimkus, ...
Medical Oncology 33, 1-7, 2016
512016
Multi-kinase inhibitors, AURKs and cancer
J Cicenas, E Cicenas
Medical Oncology 33, 1-11, 2016
502016
Protein chip based miniaturized assay for the simultaneous quantitative monitoring of cancer biomarkers in tissue extracts
U Weissenstein, MJ Schneider, M Pawlak, J Cicenas, ...
Proteomics 6 (5), 1427-1436, 2006
452006
The expression of cancer stem cell markers in human colorectal carcinoma cells in a microenvironment dependent manner
V Stankevicius, L Kunigenas, E Stankunas, K Kuodyte, E Strainiene, ...
Biochemical and biophysical research communications 484 (4), 726-733, 2017
352017
Proteomic identification of FLT3 and PCBP3 as potential prognostic biomarkers for pancreatic cancer
M Ger, A Kaupinis, M Petrulionis, B Kurlinkus, J Cicenas, A Sileikis, ...
Anticancer research 38 (10), 5759-5765, 2018
272018
JNK inhibitors: is there a future?
J Cicenas
MAP Kinase 4 (1), 2015
182015
SGK1 in cancer: Biomarker and drug target
J Cicenas, E Meskinyte-Kausiliene, V Jukna, A Rimkus, J Simkus, ...
Cancers 14 (10), 2385, 2022
172022
Quantitative proteomic analysis of anticancer drug RH1 resistance in liver carcinoma
M Ger, A Kaupinis, A Nemeikaite-Ceniene, J Sarlauskas, J Cicenas, ...
Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics 1864 (2), 219-232, 2016
172016
系统目前无法执行此操作,请稍后再试。
文章 1–20